European Companies Search Engine
EU funding (€20.3M): Communication strategy and tools for optimizing the impact of Ebola vaccination deployment – Sofia ref.: 115847 Hor1 Dec 2014 EU Research and Innovation programme "Horizon"
Text
Communication strategy and tools for optimizing the impact of Ebola vaccination deployment – Sofia ref.: 115847
Communication strategy and tools for optimizing the impact of Ebola vaccination deployment. The EBODAC consortium consists of 4 partners: Janssen (EFPIA), London School of Hygiene and Tropical Medicine (LSHTM), World Vision of Ireland and Grameen Foundation . These partners have experience and expertise in: • (Ebola) vaccine development and vaccine acceptance; m-health deployments for disease management in resource limited settings (Janssen) • Vaccine acceptance; risk management in health programs (LSHTM) • Mobile health deployments for emergency assistance; communication and training delivery in emergency settings (World Vision) • Mobile health software development and deployment in resource limited settings (Grameen) As such, the EBODAC consortium is well placed to tackle the challenges associated with Ebola vaccine deployment, including: • Stigma related to Ebola infections • Lack of understanding and distrust versus vaccines in general in the local endemic communities • Two step prime/booster regimen for Ebola vaccine: risk for a ‘no show’ for the booster shot, risk for presenting for the booster shot too early or too late; risk for a different person presenting for the booster shot vs. the prime shot • People may be difficult to reach for the vaccine recall; People may live at a large distance from the health center where the vaccine is delivered • Risk for data on vaccine coverage to be fragmented, not existing or incorrect The EBODAC consortium is committed to deliver: • A communication strategy that will optimize vaccine acceptance, supported by local anthropology research data • A platform, based on mobile phone technology, for Ebola vaccine recalls, information/education on Ebola and vaccines in general; and tracking of vaccination coverage • An identification tool to allow to match the identity of individuals in the prime and boost vaccine regimens • A training program in the local setting, and a helpdesk function, to support the m-health platform
Funded Companies:
| Company name | Funding amount |
| GRAMEEN Foundation USA | €3,454,516 |
| Janssen Pharmaceutica N.V. | €0.00 |
| London School of Hygiene and Tropical Medicine Royal Charter | €3,380,903 |
| WORLD VISION INTERNATIONAL | €0.00 |
| World Vision of Ireland LBG | €13.5M |
| World Vision Sierra Leone | €0.00 |
Source: https://cordis.europa.eu/project/id/115847
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "GRAMEEN Foundation USA - EU funding (€20.3M): Communication strategy and tools for optimizing the impact of Ebola vaccination deployment – Sofia ref.: 115847"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
